Immunotherapy and tumor microenvironment

被引:274
作者
Tang, Haidong
Qiao, Jian
Fu, Yang-Xin [1 ]
机构
[1] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA
基金
美国国家卫生研究院;
关键词
Tumor microenvironment; Tumor-infiltrating immune cells; Checkpoint blockade; CAR T-cell therapy; Chemokine Cytokine; INNATE IMMUNE RECOGNITION; MODIFIED T-CELLS; ANTITUMOR-ACTIVITY; ANTI-PD-L1; ANTIBODY; CANCER; CHEMOKINES; RESPONSES; LYMPHOCYTES; TOLERANCE; BLOCKADE;
D O I
10.1016/j.canlet.2015.10.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent exciting progress in cancer immunotherapy has ushered in a new era of cancer treatment. Immunotherapy can elicit unprecedented durable responses in advanced cancer patients that are much greater than conventional chemotherapy. However, such responses only occur in a relatively small fraction of patients. A positive response to immunotherapy usually relies on dynamic interactions between tumor cells and immunomodulators inside the tumor microenvironment (TME). Depending on the context of these interactions, the TME may play important roles to either dampen or enhance immune responses. Understanding the interactions between immunotherapy and the TME is not only critical to dissect the mechanisms of action but also important to provide new approaches in improving the efficiency of current immunotherapies. In this review, we will highlight recent work on how the TME can influence the efficacy of immunotherapy as well as how manipulating the TME can improve current immunotherapy regimens in some cases. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:85 / 90
页数:6
相关论文
共 89 条
[1]   Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity [J].
Adusumilli, Prasad S. ;
Cherkassky, Leonid ;
Villena-Vargas, Jonathan ;
Colovos, Christos ;
Servais, Elliot ;
Plotkin, Jason ;
Jones, David R. ;
Sadelain, Michel .
SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (261)
[2]   Immune checkpoint combinations from mouse to man [J].
Ai, Midan ;
Curran, Michael A. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (07) :885-892
[3]   MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF A MURINE LIGAND FOR CD40 [J].
ARMITAGE, RJ ;
FANSLOW, WC ;
STROCKBINE, L ;
SATO, TA ;
CLIFFORD, KN ;
MACDUFF, BM ;
ANDERSON, DM ;
GIMPEL, SD ;
DAVISSMITH, T ;
MALISZEWSKI, CR ;
CLARK, EA ;
SMITH, CA ;
GRABSTEIN, KH ;
COSMAN, D ;
SPRIGGS, MK .
NATURE, 1992, 357 (6373) :80-82
[4]   CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans [J].
Beatty, Gregory L. ;
Chiorean, Elena G. ;
Fishman, Matthew P. ;
Saboury, Babak ;
Teitelbaum, Ursina R. ;
Sun, Weijing ;
Huhn, Richard D. ;
Song, Wenru ;
Li, Dongguang ;
Sharp, Leslie L. ;
Torigian, Drew A. ;
O'Dwyer, Peter J. ;
Vonderheide, Robert H. .
SCIENCE, 2011, 331 (6024) :1612-1616
[5]   Help for cytotoxic-T-cell responses is mediated by CD40 signalling [J].
Bennett, SRM ;
Carbone, FR ;
Karamalis, F ;
Flavell, RA ;
Miller, JFAP ;
Heath, WR .
NATURE, 1998, 393 (6684) :478-480
[6]   Functions of cell surface heparan sulfate proteoglycans [J].
Bernfield, M ;
Götte, M ;
Park, PW ;
Reizes, O ;
Fitzgerald, ML ;
Lincecum, J ;
Zako, M .
ANNUAL REVIEW OF BIOCHEMISTRY, 1999, 68 :729-777
[7]   PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells [J].
Blank, C ;
Brown, I ;
Peterson, AC ;
Spiotto, M ;
Iwai, Y ;
Honjo, T ;
Gajewski, TF .
CANCER RESEARCH, 2004, 64 (03) :1140-1145
[8]   Human tumor antigens recognized by T lymphocytes [J].
Boon, T ;
vanderBruggen, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) :725-729
[9]   Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy [J].
Bouchlaka, Myriam N. ;
Sckisel, Gail D. ;
Chen, Mingyi ;
Mirsoian, Annie ;
Zamora, Anthony E. ;
Maverakis, Emanual ;
Wilkins, Danice E. C. ;
Alderson, Kory L. ;
Hsiao, Hui-Hua ;
Weiss, Jonathan M. ;
Monjazeb, Arta M. ;
Hesdorffer, Charles ;
Ferrucci, Luigi ;
Longo, Dan L. ;
Blazar, Bruce R. ;
Wiltrout, Robert H. ;
Redelman, Doug ;
Taub, Dennis D. ;
Murphy, William J. .
JOURNAL OF EXPERIMENTAL MEDICINE, 2013, 210 (11) :2223-2237
[10]   Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].
Brahmer, Julie R. ;
Tykodi, Scott S. ;
Chow, Laura Q. M. ;
Hwu, Wen-Jen ;
Topalian, Suzanne L. ;
Hwu, Patrick ;
Drake, Charles G. ;
Camacho, Luis H. ;
Kauh, John ;
Odunsi, Kunle ;
Pitot, Henry C. ;
Hamid, Omid ;
Bhatia, Shailender ;
Martins, Renato ;
Eaton, Keith ;
Chen, Shuming ;
Salay, Theresa M. ;
Alaparthy, Suresh ;
Grosso, Joseph F. ;
Korman, Alan J. ;
Parker, Susan M. ;
Agrawal, Shruti ;
Goldberg, Stacie M. ;
Pardoll, Drew M. ;
Gupta, Ashok ;
Wigginton, Jon M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465